InvestorsHub Logo
Followers 3
Posts 72
Boards Moderated 0
Alias Born 01/06/2007

Re: jessme post# 23608

Thursday, 05/22/2008 4:54:39 PM

Thursday, May 22, 2008 4:54:39 PM

Post# of 346050
Jessme,

"Any data is still just animal data correct?"
Yes, and you may be right as far as its immediate impact on the pps. But, I think what you are missing is the importance of outside validation for our technology. Even if they aren't mentioning bavi by name, these papers that Jazz mentions are important because they are painting the picture as to why PS may be a hugely important mechanism in disease. What jazz is leading to is that these upcomg papers from Duke will involve further validation, and information concerning TARGETING PS, and hopefully, it will show how incredibly promising this is going to be. I am not aware of anyone else who is involved in targeting PS with a proven safe antibody, which means from time of discovery to putting an antibody through animal studies, phase 1, phase 2 trials means that PPHM has a huge leg up on anyone else that wishes to follow suit...meaning if the technology continues to prove itself, especially with the upcoming phase 2 breast cancer data, then we are sitting on a very valuable platform. Add on top of that the fact that we know it should be effective in any solid tumor (vs many antibodies that are specific for one type of cancer, then even specific subtypes of cancer, ex HER-2 + breast cancer and trastuzumab) and the upcomg data out of duke showing its potential effectiveness in HIV, and you have the potential for a huge blockbuster. Not to mention, the fact that we know bavi was originally designed to take a payload of chemo/radiation, and those conjugates will be up next for testing...and also the animal studies showing that bavi with irradiated dead cancer cells acts like a vaccine against future cancer.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News